首站-论文投稿智能助手
典型文献
Targeting PP2A for cancer therapeutic modulation
文献摘要:
Protein phosphatases play essential roles as negative regulators of kinases and signaling cascades involved in cytoskeletal organization. Protein phosphatase 2A (PP2A) is highly conserved and is the predominant serine/threonine phosphatase in the nervous system, constituting more than 70% of all neuronal phosphatases. PP2A is involved in diverse regulatory functions, including cell cycle progression, apoptosis, and DNA repair. Although PP2A has historically been identified as a tumor suppressor, inhibition of PP2A has paradoxically demonstrated potential as a therapeutic target for various cancers. LB100, a water-soluble, small-molecule competitive inhibitor of PP2A, has shown particular promise as a chemo- and radio-sensitizing agent. Preclinical success has led to a profusion of clinical trials on LB100 adjuvant therapies, including a phase Ⅰ trial in extensive-stage small-cell lung cancer, a phase Ⅰ/Ⅱ trial in myelodysplastic syndrome, a phase Ⅱ trial in recurrent glioblastoma, and a completed phase Ⅰ trial assessing the safety of LB100 and docetaxel in various relapsed solid tumors. Herein, we review the development of LB100, the role of PP2A in cancer biology, and recent advances in targeting PP2A inhibition in immunotherapy.
文献关键词:
作者姓名:
Halle Ronk;Jared S.Rosenblum;Timothy Kung;Zhengping Zhuang
作者机构:
Neuro-Oncology Branch,National Cancer Institute,National Institutes of Health,Bethesda,MD 20892,USA
引用格式:
[1]Halle Ronk;Jared S.Rosenblum;Timothy Kung;Zhengping Zhuang-.Targeting PP2A for cancer therapeutic modulation)[J].癌症生物学与医学(英文版),2022(10):1428-1439
A类:
paradoxically,LB100,profusion
B类:
Targeting,PP2A,therapeutic,modulation,Protein,phosphatases,play,essential,roles,negative,regulators,kinases,signaling,cascades,involved,cytoskeletal,organization,highly,conserved,predominant,serine,threonine,nervous,system,constituting,more,than,neuronal,diverse,regulatory,functions,including,cell,cycle,progression,apoptosis,repair,Although,historically,been,identified,suppressor,inhibition,demonstrated,potential,various,cancers,water,soluble,small,molecule,competitive,inhibitor,shown,particular,promise,chemo,radio,sensitizing,agent,Preclinical,success,led,trials,adjuvant,therapies,phase,extensive,stage,lung,myelodysplastic,syndrome,recurrent,glioblastoma,completed,assessing,safety,docetaxel,relapsed,solid,tumors,Herein,we,review,development,biology,recent,advances,targeting,immunotherapy
AB值:
0.576627
相似文献
Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases
Qing Wang;Li-Juan Song;Zhi-Bin Ding;Zhi Chai;Jie-Zhong Yu;Bao-Guo Xiao;Cun-Gen Ma-Research Center of Neurobiology,The Key Research Laboratory of Benefiting Qi for Acting Blood Circulation Method to Treat Multiple Sclerosis of State Administration of Traditional Chinese Medicine,Shanxi University of Chinese Medicine,Jinzhong,Shanxi Province,China;Department of Physiology,Shanxi Medical University,Taiyuan,Shanxi Province,China;Institute of Brain Science,Shanxi Key Laboratory of Inflammatory Neurodegenerative Diseases,Shanxi Datong University,Datong,Shanxi Province,China;Department of Neurology,Datong Fifth People's Hospital,Datong,Shanxi Province,China;Institute of Neurology,Huashan Hospital,Institutes of Brain Science and State Key Laboratory of Medical Neurobiology,Fudan University,Shanghai,China
A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models
Ming Ji;Dongjie Wang;Songwen Lin;Chunyang Wang;Ling Li;Zhihui Zhang;Jing Jin;Deyu Wu;Yi Dong;Heng Xu;Duo Lu;Xiaoguang Chen-State Key Laboratory of Bioactive Substances and Functions of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China
Preclinical studies of the triazol0[1,5-a]pyrimidine derivative WS-716 as a highly potent,specific and orally active P-glycoprotein(P-gp)inhibitor
Sai-Qi Wang;Qiu-Xu Teng;Shuai Wang;Zi-Ning Lei;Hui-Hui Hu;Hui-Fang Lv;Bei-Bei Chen;Jian-Zheng Wang;Xiao-Jing Shi;Wei-Feng Xu;Hong-Min Liu;Xiao-Bing Chen;Zhe-Sheng Chen;Bin Yu-Department of Oncology,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Henan Cancer Institute,Zhengzhou 450008,China;State Key Laboratory of Esophageal Cancer Prevention&Treatment,Zhengzhou University,Zhengzhou 450052,China;College of Pharmacy and Health Sciences,St.John,s University,Queens,NY 11439,USA;School of Pharmaceutical Sciences,Zhengzhou University,Zhengzhou 450001,China;Laboratory Animal Center,Academy of Medical Science,Zhengzhou University,Zhengzhou 450052,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
Pharmacodynamic,pharmacokinetic,and phase 1a study of bisthianostat,a novel histone deacetylase inhibitor,for the treatment of relapsed or refractory multiple myeloma
Yu-bo Zhou;Yang-ming Zhang;Hong-hui Huang;Li-jing Shen;Xiao-feng Han;Xiao-bei Hu;Song-da Yu;An-hui Gao;Li Sheng;Ming-bo Su;Xiao-li Wei;Yue Zhang;Yi-fan Zhang;Zhi-wei Gao;Xiao-yan Chen;Fa-jun Nan;Jia Li;Jian Hou-National Center for New Drug Screening,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Yantai Key Laboratory of Nanomedicine&Advanced Preparations,Yantai Institute of Materia Medica,Yantai 264000,China;Department of Hematology,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Shanghai Center for Drug Metabolism and Pharmacokinetics Research,Shanghai 201203,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。